CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

The analysts say a bundle is a better model for traditional TV giants like WBD, Disney, and Paramount. Netflix is another ...

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

The widely followed cryptocurrency analyst Benjamin Cowen is warning that Ethereum (ETH) could slide further against Bitcoin ...

Cowen challenged students to rethink the intersection of society and artificial intelligence at a Yale Political Union debate ...

TD Cowen maintained a positive stance on Planet Fitness (NYSE:PLNT) shares, reiterating a Buy rating and a price target of ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

In a report released today, Marc Bianchi from TD Cowen maintained a Buy rating on NOV (NOV – Research Report), with a price target of $22.00.

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

TD Cowen analyst John Kernan maintained a Hold rating on Under Armour (UAA – Research Report) today and set a price target of $10.00. The ...

Closely followed crypto analyst Benjamin Cowen says that a shift in monetary policy will most likely be what finally triggers an "altseason," or a period where altcoins vastly outperform Bitcoin (BTC) ...

DeepSeek has quickly gained attention in AI with its R1 model, which delivers high performance at a lower cost.